ClinicalTrials.gg
Not yet recruitingNCT07791004Updated Aug 27, 2026

Deciphering Persistent Orofacial Pain - PIFP

An observational study in Persistent Idiopathic Facial Pain (PIFP), sponsored by Universitätsklinikum Hamburg-Eppendorf. Not yet recruiting at 1 site in Germany. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-08-27.

Sponsored by Universitätsklinikum Hamburg-Eppendorf · Observational

Study type
Observational
Model
Case-control
Time perspective
Prospective
Enrollment
60
Ages
18 Years to 65 Years
Sex
All
01

Study summary

Persistent non-dental orofacial pain is common yet poorly characterised, and its pathophysiology remains largely unknown. Two clinically similar entities are distinguished: post-traumatic trigeminal neuropathic pain (PTNP), in which peripheral nerve damage is demonstrable, and persistent idiopathic facial pain (PIFP), in which peripheral findings are typically absent - pointing to an altered central processing of trigeminal nociceptive input. This monocentric study characterises the peripheral and central mechanisms of PIFP by comparing PIFP patients with age- and sex-matched healthy controls using a combination of non-invasive peripheral and central approaches.

The study comprises two work packages. The peripheral work package uses quantitative sensory testing (standardised DFNS protocol) to test the hypothesis that PIFP patients retain an intact peripheral nervous system. The central work package uses functional MRI with standardised trigemino-nociceptive stimulation to characterise brainstem network dynamics, testing the hypothesis that PIFP patients exhibit a central trigeminal processing disturbance at the brainstem level. In PIFP patients, the functional MRI is repeated before and after a local-anaesthetic nerve block in the pain area, additionally distinguishing patients whose pain is completely abolished by the block from those with persistent pain despite it. The overarching aim is to characterise the pathophysiological basis of PIFP and thereby advance the mechanistic understanding of persistent orofacial pain.

Read the detailed description

Background and Rationale:

Persistent non-dental orofacial pain is common but poorly understood, and its underlying pathophysiology remains largely undefined. Two clinically similar entities can be distinguished. Painful post-traumatic trigeminal neuropathy (PTNP) is characterized by persistent pain accompanied by demonstrable somatosensory changes (negative signs such as hypoesthesia and hypoalgesia, and/or positive signs such as allodynia and hyperalgesia) in the painful area, typically following nerve injury. Persistent idiopathic facial pain (PIFP; formerly "atypical facial pain") is a constant, dull, poorly localized facial pain that does not follow the distribution of a single trigeminal branch, may cross the midline over time, and is not associated with a neuralgiform pain component; clinical and radiographic examinations are unremarkable. Because the two conditions are clinically nearly identical, patients frequently attribute the pain to dental causes, and unnecessary dental treatment or tooth extraction can aggravate and chronify the pain.

The absence of somatosensory deficits in PIFP suggests that altered central processing of trigeminal nociceptive input, rather than a purely peripheral mechanism, contributes to the pain. This is consistent with the concept of nociplastic pain, in which centrally altered sensory processing and pain modulation drive an augmented pain response. Prior high-resolution brainstem functional MRI (fMRI) work demonstrated that PIFP patients show stronger activation of the spinal trigeminal nucleus in response to standardized trigeminal nociceptive stimulation compared with healthy controls. However, fMRI alone cannot distinguish central sensitization (top-down) from a peripheral drive maintained by ongoing nociceptor input. This study therefore combines quantitative sensory testing (QST) with a trigemino-nociceptive fMRI paradigm that incorporates a peripheral nerve block, in order to characterize the peripheral and central contributions to PIFP.

Objectives and Hypotheses:

The overarching objective is to describe and characterize the pathophysiology of PIFP by comparing PIFP patients with age- and sex-matched healthy controls using non-invasive psychophysical and neuroimaging methods. The central hypothesis is that PIFP patients exhibit a disturbance of central trigeminal nociceptive processing at the brainstem level and in other critical trigeminal pain-processing regions, such as the thalamus and insula, that distinguishes them from healthy controls. A secondary hypothesis is that, within PIFP patients, a peripheral anesthetic nerve block will separate individuals whose pain is driven peripherally (pain abolished during the block) from those whose pain is maintained centrally/nociplastically (pain persists despite cutaneous numbness), and that these subgroups differ in their central nociceptive processing.

Study Procedure:

Participants are assigned to groups by clinical diagnosis; there is no randomization or blinding. Two components are applied to all participants: standardized psychophysical/sensory characterization and task-based fMRI with standardized electrical trigemino-nociceptive stimulation. Patients are recruited through the headache/facial pain outpatient clinic; healthy volunteers are recruited via public postings and local internet platforms. The study plans to enroll 30 patients with PIFP together with 30 age- and sex-matched healthy controls for comparison. Patients are recruited through the headache/facial pain outpatient clinic; healthy volunteers are recruited via public postings and local internet platforms.

Clinical and Psychophysical Characterization:

All participants complete standardized questionnaires for deep phenotyping, including the Patient Health Questionnaire (PHQ-9), central sensitization inventory (CSI), brief pain inventory (BPI), short form-36 health survey (SF-36), and custom instruments covering general health, medication and stimulant use, dental history, and oral hygiene, as well as detailed pain history, pain character and intensity, prior treatments, and potential triggering events. Patients undergo a standardized extraoral and intraoral dental examination, including palpation of the trigeminal exit points and masticatory apparatus and standardized oral health indices. Quantitative sensory testing is performed in all participants over the trigeminal dermatomes bilaterally, following the standardized protocol of the German Research Network on Neuropathic Pain (DFNS). Thermal thresholds are assessed with a thermal sensory analyzer, and mechanical stimuli with von Frey filaments and Pinprick stimulators.

Functional MRI Paradigm:

Task-based fMRI is acquired on a 3T scanner using a brainstem-optimized high-resolution protocol. Standardized nociceptive stimulation is delivered via an MR-compatible constant-current stimulator coupled to MR-safe electrodes positioned over the second (V2) and third (V3) branches of the trigeminal nerve bilaterally. After determination of individual electrical pain thresholds, stimulation intensity is set at 3 times the pain threshold and capped at 10 mA to remain tolerable and safe. Four stimulation sites, bilateral V2 and V3, are presented in randomized order with repeated trials across sessions, and participants rate perceived pain intensity after the first trial and for every 10 trials on each stimulation site. This paradigm probes the functional representation of trigeminal nociceptive input in the spinal trigeminal nucleus, thalamus, insula, and related brainstem structures.

PIFP patients who consent are scanned twice with this paradigm: before and after a local-anesthetic nerve block administered in the painful area by a dentist. This design distinguishes patients in whom the pain is abolished while the area is anesthetized (suggesting a predominantly peripheral, nociceptor-driven mechanism) from those in whom cutaneous numbness is achieved but the pain persists (suggesting a central, nociplastic mechanism).

Outcome Measures:

The primary outcome is the difference in the fMRI response to standardized trigemino-nociceptive stimulation within trigeminal pain-processing regions - including the spinal trigeminal nucleus, thalamus, and insula - in the following comparisons: (i) PIFP patients versus healthy controls; and (ii) within PIFP patients, the difference in activation before versus after the local-anesthetic nerve block, and between patients whose pain is completely abolished by the block versus those with persistent pain despite the block. Secondary outcome includes: (1) comparison of deep phenotyping and QST parameters between PIFP patients and healthy controls

Statistical Analysis:

The primary analysis requires 20 complete datasets per cohort. Based on previous studies with this population and sequence, approximately 25% of enrolled participants are expected to yield unusable data (dropout, excessive head motion, or incidental findings). Neuroimaging data are analyzed using a general linear model with statistical parametric mapping, contrasting the painful side versus the control side, and comparing groups and pre/post nerve-block conditions. For the fMRI data, a family-wise error-corrected threshold of PFWE \< 0.05 will be applied at the whole-brain level, except for a priori regions of interest - the spinal trigeminal nucleus, thalamus, and insula - for which small-volume-corrected PFWE \< 0.05 will be used. Psychophysical and QST parameters are compared between groups using parametric or non-parametric tests as appropriate after testing distributional assumptions, with a two-sided significance level of p \< 0.05. Analyses are performed after completion of data collection; no interim analyses are planned.

02

Conditions studied

  • Persistent Idiopathic Facial Pain (PIFP)

Browse trials for

Keywords

  • PIFP
  • fMRI
  • atypical facial pain
  • nerve block
  • local anesthesia
03

In context

Facial Pain

182 studies on the registry are indexed under Facial Pain; 61 are open to participants now.

This study's planned enrollment of 60 is below the median of 101 across 42 observational studies indexed under Facial Pain.

Browse Facial Pain studies →

Lead sponsor

Universitätsklinikum Hamburg-Eppendorf is the lead sponsor of 416 studies on the registry; 86 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Patients with PIFP will be recruited from the headache/facial pain outpatient clinic of the University Medical Center Hamburg-Eppendorf

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy controls: written .
  • PIFP cohort: written informed consent, and a diagnosis of PIFP according to the ICHD-3 and ICOP diagnostic criteria.

Exclusion criteria

Exclusion Criteria:

  • to MR scanning
  • Anxiety disorders, including claustrophobia
  • Other somatic diseases, including other pain disorders
  • Other primary headache disorders and medication-overuse headache
  • Skin lesion , infection, or scarring at the stimulation sites preventing safe electrode placement
  • Healthy volunteers: any history of persistent pain or primary headache, including in first-degree relatives
  • History of psychiatric disease and/or addiction
  • Pregnancy or lactation
  • Any regular medication; in PIFP patients, occasional acute analgesic use (NSAID, fewer than 8 days per month) is permitted
  • Use of acute analgesic within 24 hours before the experiment
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Observational model
Case-control
Time perspective
Prospective
Enrollment
60 participants (estimated)
Patient registry
No

Groups and cohorts

  • Patients with persistent idiopathic facial pain (PIFP)

    Patients with persistent idiopathic facial pain

  • Age- and sex-matched healthy controls (HC)
06

What researchers measure

Primary outcomes

  1. Difference in brain functional neuroimaging response to standardized trigemino-nociceptive stimulation between PIFP patients HC

    BOLD signal change (contrast estimates, arbitrary units) during standardized trigemino-nociceptive stimulation versus baseline, compared between PIFP patients and HC in a priori defined regions of interest and at whole-brain level.

    Time frame: Baseline (MRI session before local anesthesia)

  2. Difference in brain activation before versus after the local-anesthetic nerve block, and between complete responders and non-responders

    BOLD signal change (contrast estimates, arbitrary units) during standardized trigemino-nociceptive stimulation, compared within participants before versus after the local-anesthetic nerve block, and between participants whose pain is completely abolished by the block and those with persistent pain despite the block

    Time frame: Pre-block MRI at baseline and post-block MRI, both on the same day 1

Secondary outcomes

  1. Comparison of deep phenotyping and quantitative sensory testing (QST) parameters between the study cohorts (PIFP versus HC).

    Standardized DFNS quantitative sensory testing parameters (thermal and mechanical detection and pain thresholds), compared between PIFP patients and HC.

    Time frame: Baseline (single assessment before local anesthesia)

07

Study locations

1 site
08

References and documents

Publications

  • Ziegeler C, Schulte LH, May A. Altered trigeminal pain processing on brainstem level in persistent idiopathic facial pain. Pain. 2021 May 1;162(5):1374-1378. doi: 10.1097/j.pain.0000000000002126. PubMed 33110030 ↗
  • Mehnert J, Basedau H, Sturm LM, Nielsen T, Jensen RH, May A. Functional brainstem representations of the human trigeminal cervical complex. Cephalalgia. 2023 May;43(5):3331024231174862. doi: 10.1177/03331024231174862. PubMed 37203351 ↗
  • May A, Ciancia V, Basedau H. Visualizing nociplastic pain: functional hyperexcitability in neuropathic and idiopathic facial pain syndromes. J Headache Pain. 2025 Oct 13;26(1):211. doi: 10.1186/s10194-025-02133-w. PubMed 41083924 ↗

Individual participant data

Plan to share: No — Individual participant data (IPD) will not be shared with other researchers. Data are collected and analyzed in pseudonymized form, and results will be reported and published only in aggregated, anonymized form that does not permit identification of individual participants. The pseudonymization key is held exclusively by the study leadership and is deleted as soon as the research purpose allows. Consistent with the informed consent obtained from participants and the approved data protection concept, no de-identified individual-level datasets will be made available externally.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Sep 2026; primary completion for Jun 2029, 33 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 18, 2026
First posted
Aug 27, 2026
StartEst.
Sep 1, 2026
Primary completionEst.
Jun 30, 2029
CompletionEst.
Oct 31, 2029
Last update
Aug 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 27, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07791004
Responsible party
Kuan-Po Peng (Research Associate, Universitätsklinikum Hamburg-Eppendorf) — Principal investigator
First posted
Aug 27, 2026
Start date
Sep 1, 2026 (estimated)
Primary completion
Jun 30, 2029 (estimated)
Completion
Oct 31, 2029 (estimated)
Last update
Aug 27, 2026

Study contacts

Arne May, MD, PhD
Contact
a.may@uke.de
+49 40 74105 9189
Kuan-Po Peng, MD
Contact
k.peng@uke.de
+49 40 74102 7305
Arne May, MD, PhD
principal investigator · Department of Systems Neuroscience, University Medical Center Hamburg-Eppendorf

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion